In the recent ixekizumab study, 72.5% of the 95 genes in the IL-17 treated RHE model that were also part of the MAD-3 psoriasis transcriptome improved by over 75% at two weeks post-treatment compared with 68% of all psoriasis genes (Figure 3C) [41]. The gene discussed is IL17A; the disease is psoriasis.